dallas semaglutide constipation class action Ozempic Lawsuit Settlement Amounts [2026 Projections]

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

24.20

★★★★☆4.8 (126)

Spotlight on the Mechanism of Action of Semaglutide

25.80

★★★★★4.9 (98)

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity

28.76

★★★★★5.0 (157)

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

28.24

★★★★★4.7 (84)

Ozempic constipation: Why it happens and how to treat it

25.90

★★★★★4.9 (203)

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit

21.21

★★★★★5.0 (176)

Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management

21.79

★★★★★4.8 (132)